Dubois C, Blanchard D
CMC Foch, Service de Chirurgie Cardiovasculaire, Suresnes, France.
Clin Ther. 1989 Jul-Aug;11(4):452-60.
The efficacy and safety of nicardipine were assessed in 29,104 hypertensive patients (mean age, 64 years) during a 90-day multicenter clinical trial. By treatment day 90, blood pressure was controlled in 60% of the patients taking nicardipine alone. The efficacy of nicardipine combined with another antihypertensive agent was examined in 6,479 of the patients. When nicardipine was added to their treatment regimen, blood pressure was controlled by day 90 in 63% of the patients taking beta-blockers, in 58% of those on diuretics, in 50% of those on angiotensin converting enzyme inhibitors, and in 49% of those taking centrally acting antihypertensive agents. Nicardipine was well tolerated; only 11% of the 29,104 patients discontinued treatment because of side effects. Most adverse reactions were transient and were related to vasodilation, and included peripheral edema in 7% of the patients, flushing in 7%, and headache in 4%. The results indicate that nicardipine is suitable as initial therapy in arterial hypertension.
在一项为期90天的多中心临床试验中，对29104例高血压患者（平均年龄64岁）评估了尼卡地平的疗效和安全性。到治疗第90天时，单用尼卡地平的患者中有60%血压得到控制。在6479例患者中检查了尼卡地平与另一种抗高血压药物联合使用的疗效。当将尼卡地平添加到他们的治疗方案中时，到第90天时，服用β受体阻滞剂的患者中有63%血压得到控制，服用利尿剂的患者中有58%，服用血管紧张素转换酶抑制剂的患者中有50%，服用中枢性抗高血压药物的患者中有49%血压得到控制。尼卡地平耐受性良好；在29104例患者中，只有11%因副作用而停药。大多数不良反应是短暂的，与血管扩张有关，包括7%的患者出现外周水肿，7%出现潮红，4%出现头痛。结果表明，尼卡地平适合作为动脉高血压的初始治疗药物。
